Lonza, a global leader in the biopharmaceutical manufacturing industry, has secured a substantial £30 million subsidy to expand its biologics facility in the United Kingdom. This funding, provided by the UK government, is part of a strategic initiative to bolster the country’s life sciences sector and enhance its capabilities in biologics production.
The subsidy will be directed towards the expansion of Lonza’s Slough site, which is a key location for the company’s biologics manufacturing operations. The planned expansion will increase the facility’s capacity to meet the growing demand for biologic drugs, which are essential in treating a range of chronic and complex diseases, including cancer and autoimmune disorders.
The investment is expected to create hundreds of new jobs and further solidify the UK’s position as a leading hub for biopharmaceutical manufacturing. Additionally, the expansion aligns with Lonza’s broader strategy to scale up its global production capacity, ensuring the company can support the development and commercialization of new therapies.
This move underscores the UK government’s commitment to supporting the life sciences industry, particularly in the wake of recent challenges posed by global supply chain disruptions. The expansion of the Slough site will not only enhance Lonza’s operational capabilities but also contribute to the overall resilience of the UK’s healthcare infrastructure.
Lonza’s expansion in the UK is anticipated to be completed by 2026, with the enhanced facility poised to play a crucial role in the production of next-generation biologics.
Join us for a groundbreaking event focused on the digitalization and AI integration in the global biopharma industry, valued at around USD 1.78 billion in 2022 and projected to surpass $2.47 billion by 2027. The APAC region is rapidly advancing in digitalization, supported by strategic government incentives. Our event on September 10th will feature a dedicated track on Biologics Digitalization & AI, bringing together APAC leaders who have successfully implemented AI and digitalization in R&D, manufacturing, quality, and supply chain to enhance efficiency, productivity, and cost-effectiveness. Find out more at: https://imapac.com/events/biologics-digitalisation-and-ai-world/
